Nektar Therapeutics presented new biomarker data in a late-breaking oral session at the European Academy of Dermatology & Venereology Congress 2026, showing early molecular responses to rezpegaldesleukin across multiple immune pathways dysregulated in patients with atopic dermatitis. The company also plans two other oral presentations, including six-month off-treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Nektar, a US-based immunotherapy developer with a reported market value of about $2.1 billion, has FDA Fast Track designation in both conditions and says its cash runway extends into Q3 2028. The October 1, 2026 investor call is expected to provide a checkpoint on 24-week off-treatment data and potential Phase 3 timing in early 2027. The analysis frames the readouts as important to the investment case, which balances the asset's potential against concentration in one drug, ongoing losses and past dilution, and cites a $144 fair value. It also flags three warning signs, two considered major, while noting that the article is general commentary rather than financial advice.